Clinical trials: Triple Branch
Estrogen Receptor Negative, HER2/Neu Negative
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast cancer (breast cancer cells that do not have…
- Conditions
- Estrogen Receptor Negative, HER2/Neu Negative, Invasive Breast Carcinoma, Progesterone Receptor Negative
- Trial name
- NCT01964924
- Testing
- Akt Inhibitor GSK2141795, Laboratory Biomarker Analysis, Trametinib
- Where
- 8 sites in United States
- Volunteers
- 37 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer (Triple Negative Breast Cancer (TNBC)), Chemeotherapy
A Study of Tislelizumab Combined With TAC Regimen as Neoadjuvant Therapy for TNBC
To assess the efficacy and safety of tislelizumab combined with TAC as neoadjuvant therapy for triple-negative breast cancer, and to preliminarily investigate its underlying molecular mechanisms.
- Trial name
- NCT07827079
- Testing
- Nab paclitaxel/Carboplatin, anthracyclines,Tislelizumab
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
HIV II Infection
Dolutegravir Plus 2 NRTIs, in Treatment-Naïve HIV-2 Infected Subjects
Multicenter, single-arm, open-label clinical trial to evaluate the efficacy, the safety and the tolerability of 50 mg dolutegravir once daily (q.d.) given in combination with 2 NRTIs backbone in HIV-2 positive, treatment-naïve…
- Trial name
- NCT03224338
- Testing
- Dolutegravir 50 mg
- Where
- 6 sites in Portugal
- Volunteers
- 30 people
- Sponsor
- Blueclinical, Ltd.
Triple-negative Breast Cancer, Bone Metastases
Tislelizumab Combined with Nab-Paclitaxel for First-Line Treatment of Advanced Triple-Negative Breast Cancer with Bone Metastasis，an Exploratory, Single-Arm, Multicenter Phase II Clinical Study
The goal of this clinical trial is to learn if Tislelizumab Combined with Nab-Paclitaxel works to treat patients of TNBC with bone metastasis as first line treatment. It will also learn about the safety of the combination.
- Trial name
- NCT06538896
- Testing
- Tislelizumab + Nab-Paclitaxel, Rankl inhibitor
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Zhejiang Cancer Hospital
Triple-Negative Breast Cancer
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy and targeted therapy are completely ineffective, chemotherapy is currently the only effective treatment.
- Trial name
- LANCET (NCT03243838)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Guangdong Provincial People's Hospital
Breast Cancer
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
To evaluate the efficacy and safety of sintilimab and bevacizumab biosimilar combined with pegylated liposomal doxorubicin in pretreated metastatic triple-negative breast cancer
- Trial name
- NCT05386524
- Testing
- sintilimab, bevacizumab biosimilar, pegylated liposomal doxorubicin
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Fudan University
Breast Cancer
A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC
This is a phase II, explorative, open-labeled, multi-centered, double-arm, investigator-initiated clinical trial of Camrelizumab (an anti-PD-1 antibody) in combination with Nab-paclitaxel (a chemotherapeutic agent against breast…
- Trial name
- NCT06632405
- Testing
- Camrelizumab, Nab paclitaxel, Levocetirizine Hydrochloride
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sleep Disorder (Healthy Volunteers)
Study to Evaluate Improvements of the Quality of Sleep With NOVANUIT® Triple Action in Healthy Volunteers With Sleep Disorders
Primary Objective: To estimate the range of improvement of NOVANUIT® triple action on sleep quality global score. Secondary Objectives: To estimate the range of improvement of NOVANUIT® triple action on following parameters: time…
- Trial name
- NCT03514732
- Testing
- MELATONIN (MELATL07959)
- Where
- Poland
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sanofi
Triple Negative Breast Cancer
Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer
This is a multicenter, open-label, non-comparative, three-arm, phase IIa trial of Ipatasertib (GDC-0068) in combination with non-taxane chemotherapy agents for taxane-pretreated unresectable locally advanced or metastatic…
- Trial name
- PATHFINDER (NCT04464174)
- Testing
- Ipatasertib, Capecitabine, Eribulin
- Where
- 14 sites in Portugal, Spain
- Volunteers
- 54 people
- Sponsor
- MedSIR
Multiple Myeloma
A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US
The purpose of the study is to understand how well elranatamab (PF-06863135) may be used for relapsed refractory multiple myeloma (RRMM).
- Trial name
- NCT06504524
- Testing
- Elranatamab, Standard of Care
- Where
- 2 sites in United States, Germany
- Volunteers
- 633 people
- Sponsor
- Pfizer
Breast Cancer, TNBC - Triple-Negative Breast Cancer
First-line Nab-paclitaxel Plus Cisplatin Plus Camrelizumab in mTNBC Patients
To evaluate the efficacy and safety of nab-paclitaxel plus cisplatin plus carilizumab as first-line treatment in patients with metastatic triple-negative breast cancer.
- Trial name
- NCT04537286
- Testing
- nab-paclitaxel plus cisplatin plus carilizumab (AP+PD-1)
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Fudan University